Exhibit 10.10
EMPLOYMENT AGREEMENT
This Employment Agreement (“Agreement”) is made between Fusion Pharmaceuticals Inc. (the “Company”), and Eric Burak (the “Executive”) and is effective as of December 18, 2023 (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the Employment Agreement between the Executive and the Company dated February 16, 2017, and the Employment Agreement dated June 25, 2020 and amended on February 19, 2021 (the “Prior Agreements”).
WHEREAS, the Executive is currently employed as the Chief Technology Officer of the Company;
AND WHEREAS, the Company desires to continue to employ the Executive and update the terms and conditions of his employment contained herein, and the Executive desires to continue to be employed as Chief Technology Officer on these new terms and conditions.
NOW, THEREFORE, in consideration of the foregoing mutual covenants and agreements contained herein and other good and valuable consideration, including a one-time retention bonus of $1,000.00 CAD, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:
IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective Date.
FUSION PHARMACEUTICALS, INC.
/s/ Maria Stahl
By: Maria Stahl
Its: Chief Legal Officer
EXECUTIVE
/s/ Eric Burak
Eric Burak
Exhibit A
Restrictive Covenants Agreement